Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase IV, 2x2 factorial, double blind study of 48 versus 96 weeks of PEGASYS 180 microg, with or without 24 weeks of entecavir in adult patients with HBeAg negative chronic hepatitis B.

Next Previous
Trial Profile

A phase IV, 2x2 factorial, double blind study of 48 versus 96 weeks of PEGASYS 180 microg, with or without 24 weeks of entecavir in adult patients with HBeAg negative chronic hepatitis B.

Status: Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 20 Feb 2017

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 25 Sep 2010 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by Roche.
  • 23 Aug 2010 New trial record
  • 13 Aug 2010 Actual end date (Nov 2014) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top